Phospholipids In Medium Vldl
Introduction
Section titled “Introduction”Phospholipids are a fundamental class of lipids essential for numerous biological processes, forming the primary structural components of cellular membranes and playing a crucial role in the transport and metabolism of fats throughout the body. Very Low-Density Lipoproteins (VLDLs) are a type of lipoprotein synthesized in the liver, primarily responsible for transporting endogenous triglycerides and cholesterol to various tissues. The phospholipid content and composition within medium VLDL particles are critical for their structural integrity, stability, and proper function in lipid metabolism. Variations in these phospholipids can impact VLDL particle size, density, and interaction with enzymes and receptors, thereby influencing overall lipid homeostasis.
Biological Basis
Section titled “Biological Basis”The synthesis and metabolism of phospholipids destined for incorporation into VLDL are complex processes involving several enzymes and genetic pathways. Glycerophospholipids, such as phosphatidylcholine (PC) and phosphatidylethanolamine (PE), are particularly significant. Genetic variants in the FADS1 and FADS2 gene cluster are strongly associated with the fatty acid composition in phospholipids [1], [2]. [3] Specifically, the FADS1 gene is involved in the synthesis of long-chain polyunsaturated fatty acids, which are then integrated into glycerophospholipids. A polymorphism in the FADS1gene shows a strong association with the concentrations of various glycerophospholipid species, including PC, PE, and phosphatidylinositol (PI), suggesting its role in phospholipids containing an arachidonyl-moiety (C20:4).[4]For instance, the strongest effect size has been observed for phosphatidylcholine diacyl C36:4 (PC aa C36:4) relative to phosphatidylcholine diacyl C36:3 (PC aa C36:3), with a single nucleotide polymorphism (SNP) explaining a significant portion of the total variance in the population.[4]
Other genes implicated in lipid metabolism, which can indirectly affect phospholipids in VLDL, include those encoding apolipoproteins (e.g.,APOA5, APOB, APOE), enzymes like lipases (LPL, LIPC, LIPG), and lipid transfer proteins like PLTP (Phospholipid Transfer Protein). For example, PLTPexpression has been linked to HDL cholesterol and triglyceride levels, suggesting its involvement in the transfer and remodeling of phospholipids within lipoproteins[5]. [6]Lipoprotein lipase (LPL) and hepatic lipase (LIPC) are crucial for the breakdown and remodeling of lipoproteins, including the processing of their phospholipid components [7]. [8]
Clinical Relevance
Section titled “Clinical Relevance”Alterations in circulating lipid levels, including the composition of phospholipids within VLDL, are well-established risk factors for cardiovascular disease (CVD) and related morbidity.[8] Dyslipidemia, characterized by abnormal lipid profiles, has a high heritability, and numerous genes and their proteins involved in lipid metabolism contribute to this condition. [8] Genetic variants influencing lipid traits are associated with polygenic dyslipidemia. [5]
Specific genetic associations with phospholipid metabolism have been identified, such as the SNP rs4775041 near LIPCwhich influences phosphatidylethanolamines and weakly associates with type 2 diabetes, bipolar disorder, and rheumatoid arthritis, highlighting phospholipids as intermediate phenotypes linking genetic variation to complex diseases.[4] Other loci associated with various lipid levels include ABCA1, CELSR2, CETP, DOCK7, GALNT2, GCKR, HMGCR, LDLR, LIPC, LIPG, LPL, MLXIPL, NCAN, PCSK9, TRIB1, MVK-MMAB, APOA5-APOA4-APOC3-APOA1, and APOE-APOC1-APOC4-APOC2 [5], [7], [8], [9], [10]. [11]These genes can directly or indirectly impact the quantity and composition of phospholipids within VLDL, affecting their metabolic fate and contribution to disease risk.
Social Importance
Section titled “Social Importance”The study of phospholipids in medium VLDL is of significant social importance due to its implications for public health. Cardiovascular diseases remain leading causes of morbidity and mortality worldwide. Understanding the genetic determinants of phospholipid composition in VLDL can lead to more precise risk stratification for individuals, allowing for earlier intervention and personalized prevention strategies for dyslipidemia and related conditions. Insights gained from these genetic studies can inform the development of novel diagnostic tools and targeted therapeutic approaches. For example, identifying specific genetic variants that influence VLDL phospholipid profiles could enable tailored dietary recommendations or pharmacological interventions to optimize lipid metabolism and reduce disease burden. Ultimately, unraveling the genetic architecture underlying phospholipid metabolism contributes to improving overall health and well-being in the population.
Limitations
Section titled “Limitations”Methodological and Statistical Constraints
Section titled “Methodological and Statistical Constraints”The interpretation of genetic associations, particularly for traits like very low-density lipoprotein (VLDL) particle concentrations, is subject to several methodological and statistical limitations inherent in discovery research. Some identified loci did not achieve the stringent statistical significance threshold of P < 5 × 10^-8, despite potentially representing genuine associations.[5] This suggests that the study might have missed certain true genetic influences on lipid metabolism, including those affecting VLDL particle concentrations, due to insufficient statistical power for weaker signals. Consequently, the reported genetic architecture may not fully capture all contributing variants, leading to an incomplete understanding of the polygenic nature of dyslipidemia.
Furthermore, relying on a prespecified significance threshold can lead to an underestimation of the total genetic contribution to complex traits. While the research identified strong signals for some specialized phenotypes, the generalizability of these findings, particularly for loci with weaker statistical evidence, may require further validation in independent and larger cohorts. [5] This limitation highlights the necessity for ongoing research to replicate these associations and to explore the broader spectrum of genetic variants that might contribute to the regulation of VLDL particle concentrations and other lipid components, even those that fall below initial discovery thresholds.
Unexplored Genetic Influences and Phenotypic Nuances
Section titled “Unexplored Genetic Influences and Phenotypic Nuances”While the study examined a range of lipid phenotypes, including VLDL particle concentrations, the intricate genetic architecture underlying the full spectrum of lipoprotein components remains an area with significant knowledge gaps. The observation that stronger genetic signals were often detected for “specialized phenotypes” suggests that broadly defined lipid measures might obscure more specific genetic effects on particular lipoprotein subfractions or compositions, such as the phospholipid content within VLDL.[5] This implies that the current research, while foundational, may not fully elucidate the genetic determinants impacting specific components of VLDL particles.
The approach of identifying common variants contributing to polygenic dyslipidemia provides a broad overview, but it inherently leaves room for further discovery regarding rare variants, structural variations, or complex gene-environment interactions that might significantly influence specific aspects of lipid metabolism. Consequently, while the study advanced understanding of common variant associations, the comprehensive genetic landscape governing the precise composition and function of VLDL particles, including their phospholipid component, likely involves additional genetic factors and regulatory mechanisms yet to be fully characterized. [5] Future investigations focusing on these nuanced aspects could provide a more complete picture of genetic contributions to lipid health.
Variants
Section titled “Variants”Genetic variations play a crucial role in regulating lipid metabolism and influencing the levels of various lipoproteins, including very-low-density lipoproteins (VLDL) and their phospholipid content. These variants impact the synthesis, processing, and clearance of lipoproteins, directly affecting cardiovascular health.
Variations in key apolipoprotein genes, such as _APOE_ and _APOB_, significantly modulate lipoprotein levels._APOE_ is a vital component of VLDL and chylomicrons, facilitating their uptake by liver cells through receptor interactions. While the specific variant rs7412 in _APOE_ requires further detailed characterization, common _APOE_alleles are known to influence how efficiently these triglyceride-rich lipoproteins are cleared from the blood, impacting overall lipid profiles and contributing to coronary artery disease risk.[12] Similarly, _APOB_is the primary structural protein for VLDL and its metabolic product, low-density lipoprotein (LDL), essential for their assembly and secretion. Thers693 variant in _APOB_is associated with alterations in both LDL cholesterol and triglyceride levels, suggesting an impact on VLDL stability or its conversion to LDL.[5]These changes directly influence the phospholipid composition and size of VLDL particles. The_TM6SF2_ gene (Transmembrane 6 Superfamily Member 2), with variant rs58542926 , also plays a critical role in regulating VLDL secretion from the liver. This variant is recognized for affecting lipid droplet formation and the export of triglycerides and phospholipids into VLDL particles, with alterations potentially leading to changes in the composition of circulating VLDL.
The receptor-mediated clearance of lipoproteins is also influenced by specific genetic variants. The _LDLR_gene encodes the Low-Density Lipoprotein Receptor, which is essential for removing LDL and VLDL remnants from circulation. Thers6511720 variant in _LDLR_ is strongly linked to LDL cholesterol concentrations, with specific alleles increasing these levels and thereby impacting overall lipid metabolism. [7] Complementing _LDLR_ function, the _PCSK9_ gene encodes a protein that promotes the degradation of the _LDLR_. Variants like rs11591147 in _PCSK9_ can alter this regulatory process, influencing the number of available _LDLR_receptors to clear lipoproteins. This directly impacts the lifespan of VLDL remnants and LDL particles, affecting plasma cholesterol and triglyceride-rich lipoprotein content.[13] The _ZPR1_ gene (Zinc Finger Protein, Recombination 1), associated with rs964184 , is involved in cellular processes like proliferation and transport; while not directly a lipid gene, its influence on cellular integrity and signaling may subtly affect hepatic lipid processing and VLDL assembly.
Other variants influence enzymes and regulatory proteins central to VLDL metabolism. _LPL_(Lipoprotein Lipase), represented by thers10096633 variant, encodes an enzyme that breaks down triglycerides in VLDL and chylomicrons, facilitating the release of fatty acids. Variants affecting_LPL_activity can lead to altered triglyceride and HDL cholesterol levels.[5] Impaired _LPL_function can result in slower clearance of triglyceride-rich VLDL, potentially altering their phospholipid-to-triglyceride ratio. The_TRIB1AL_ gene, likely referring to _TRIB1_, with variant rs112875651 , encodes a protein that regulates gene expression linked to lipid metabolism, particularly impacting triglyceride levels.[5] Variations in _TRIB1_ can therefore affect the synthesis or catabolism of VLDL, influencing the pool of phospholipids available for VLDL assembly. Furthermore, _CETP_(Cholesteryl Ester Transfer Protein), linked to thers247616 variant in the _HERPUD1_ - _CETP_ region, facilitates the exchange of cholesteryl esters and triglycerides between lipoproteins, influencing the overall phospholipid and fatty acid composition of medium VLDL particles. [8] Finally, variants near _CELSR2_ (Cadherin EGF LAG Seven-Pass G-Type Receptor 2), such as rs12740374 , are implicated in LDL cholesterol metabolism. While specific direct mechanisms for _CELSR2_are still being explored, genetic associations in this locus indicate its indirect role in pathways affecting lipoprotein particle characteristics, including VLDL.[7]
Key Variants
Section titled “Key Variants”Biological Background
Section titled “Biological Background”Phospholipids and Very-Low-Density Lipoprotein Structure
Section titled “Phospholipids and Very-Low-Density Lipoprotein Structure”Very-low-density lipoproteins (VLDL) are crucial lipid-carrying particles synthesized primarily by the liver to transport triglycerides to peripheral tissues. Phospholipids form a vital component of the VLDL structure, creating a monolayer that encapsulates the hydrophobic core of triglycerides and cholesterol esters. This amphipathic arrangement, with hydrophilic heads facing the aqueous plasma and hydrophobic tails embedded in the lipid core, ensures the stability and solubility of VLDL particles in circulation. The precise composition of these phospholipids can significantly influence the overall size, density, and metabolic fate of VLDL particles, directly impacting how these lipoproteins interact with enzymes and receptors in the bloodstream.
Genetic Determinants of Phospholipid and Lipoprotein Metabolism
Section titled “Genetic Determinants of Phospholipid and Lipoprotein Metabolism”The genetic landscape plays a substantial role in dictating both the fatty acid composition of phospholipids and overall lipoprotein levels. For instance, theFADS1 and FADS2 gene cluster encodes desaturase enzymes critical for modifying fatty acids, and common genetic variants within this cluster are associated with the specific fatty acid composition found in phospholipids. [2] This directly affects the types of phospholipids available for incorporation into VLDL particles. Furthermore, genetic variations in genes like ABCG5 and ABCG8, which encode sterol transporters, have been linked to plasma lipoprotein levels, indicating their influence on the broader lipid transport pathways that contribute to VLDL assembly and content.[14] The transcription factor HNF4Aalso exhibits functional polymorphisms associated with altered metabolic function, suggesting its regulatory impact on genes involved in lipid synthesis and lipoprotein remodeling.[15]
Systemic Regulation of Triglyceride and VLDL Dynamics
Section titled “Systemic Regulation of Triglyceride and VLDL Dynamics”The synthesis, secretion, and catabolism of very-low-density lipoproteins are tightly regulated processes that maintain lipid homeostasis. The liver is the primary organ for VLDL synthesis, packaging newly synthesized triglycerides with phospholipids and apolipoproteins for export into circulation. Once in the bloodstream, VLDL particles undergo remodeling, with their triglycerides hydrolyzed by lipoprotein lipase, an enzyme whose activity is significantly modulated by other proteins. For example, genetic variations inANGPTL4have been identified that reduce plasma triglyceride levels, indicating its role in influencing VLDL catabolism and thus the circulating concentrations of these lipoprotein particles and their phospholipid content.[16] This intricate metabolic network ensures that lipids are efficiently transported and delivered to tissues while maintaining systemic balance.
Pathophysiological Links to Dyslipidemia
Section titled “Pathophysiological Links to Dyslipidemia”Alterations in the normal composition and metabolism of phospholipids within VLDL contribute to dyslipidemia, a condition characterized by abnormal lipid levels that serves as a major risk factor for metabolic diseases. Dyslipidemia is often a polygenic trait, meaning that multiple common genetic variants across numerous loci contribute to its development. [5] When the homeostatic balance of VLDL synthesis, composition, or clearance is disrupted, it can lead to an accumulation of VLDL particles with potentially altered phospholipid profiles. Such imbalances can have systemic consequences; for example, specific polymorphisms in the HNF4Agene are associated with type 2 diabetes and changes in beta-cell function, underscoring the interconnectedness of lipid metabolism, glucose regulation, and overall metabolic health.[15] These disruptions can ultimately contribute to the progression of various metabolic disorders.
Pathways and Mechanisms
Section titled “Pathways and Mechanisms”Metabolic Pathways of Phospholipid and Triglyceride Synthesis
Section titled “Metabolic Pathways of Phospholipid and Triglyceride Synthesis”Phospholipids and triglycerides are fundamental components of very low-density lipoprotein (VLDL) particles, with their synthesis governed by intricate metabolic pathways. Phospholipids encompass diverse species such as phosphatidylethanolamines, phosphatidylcholines, and phosphatidylinositols, some of which feature plasmalogen or plasmenogen structures with varying fatty acid side chains.[17] A critical enzyme in phospholipid synthesis is encoded by the FADS1 gene, which is involved in producing long-chain polyunsaturated fatty acids (PUFAs) from essential precursors. [17] Specifically, FADS1significantly influences the efficiency of the fatty acid delta-5 desaturase reaction, a key step for generating arachidonic acid (C20:4) and other PUFAs that are subsequently incorporated into these complex glycerophospholipids.[17]
The synthesis of triglycerides, which form the core of VLDL, is transcriptionally regulated by proteins such as MLXIPL. This transcription factor activates specific motifs within the promoter regions of genes dedicated to triglyceride production, thereby controlling the overall cellular capacity for synthesizing these lipids.[18] Additionally, cholesterol biosynthesis, another pathway contributing essential components to VLDL, initiates with rate-limiting enzymes like mevalonate kinase (MVK), which catalyzes an early step in the mevalonate pathway. [19] These biosynthetic processes are subject to rigorous metabolic regulation, ensuring that the flux of phospholipids, triglycerides, and cholesterol is appropriately balanced for VLDL assembly and overall lipid homeostasis.
Lipoprotein Assembly, Remodeling, and Catabolism
Section titled “Lipoprotein Assembly, Remodeling, and Catabolism”The metabolic journey of VLDL extends beyond its initial synthesis to include dynamic assembly, remodeling, and catabolism in circulation. Apolipoprotein CIII (APOC3), a component of apoB-containing lipoproteins that originates from both the liver and intestines, plays a crucial role in impeding the catabolism and hepatic uptake of these particles. [20] Studies have shown that an increase in APOC3on VLDL particles, coupled with reduced apolipoprotein E (APOE), leads to a diminished VLDL fractional catabolic rate, contributing to conditions like hypertriglyceridemia. [21]
Key enzymes in VLDL metabolism include lipoprotein lipase (LPL), hepatic lipase (LIPC), and endothelial lipase (LIPG), which are responsible for hydrolyzing triglycerides and phospholipids within circulating lipoproteins, facilitating their modification and eventual removal from the bloodstream. [22] The activity of these lipases is tightly regulated, with proteins such as angiopoietin-like protein 3 (ANGPTL3) and angiopoietin-like protein 4 (ANGPTL4) acting as inhibitors, thereby modulating triglyceride turnover.[18]Furthermore, lipoprotein receptors like the low-density lipoprotein receptor (LDLR) are essential for the cellular uptake of lipoproteins and their remnants, while cholesterol and cholesterol ester transporters, such as ABCA1 and CETP, mediate lipid exchange between various lipoprotein classes, continuously reshaping VLDL composition and fate.[22]
Transcriptional and Post-Translational Regulation of Lipid Homeostasis
Section titled “Transcriptional and Post-Translational Regulation of Lipid Homeostasis”Genetic variations exert a significant regulatory influence over lipid metabolism, affecting both the quantity and composition of phospholipids and other lipids. Single nucleotide polymorphisms (SNPs) within theFADS gene cluster are notably associated with the fatty acid composition of phospholipids, dictating the types and ratios of polyunsaturated fatty acids available for incorporation into these molecules. [17] These genetic variants can alter the efficiency of fatty acid desaturase enzymes, directly impacting the metabolic flux through these synthetic pathways. [17]
Beyond genetic predisposition, transcriptional regulation provides another layer of control. The transcription factor MLXIPL, for instance, acts as a master regulator by binding to specific promoter regions and activating genes critical for triglyceride synthesis.[18] Similarly, genetic variants located in the promoter regions of genes like LIPCcan lead to altered hepatic lipase activity, directly influencing lipoprotein remodeling and ultimately affecting circulating lipid levels.[23] Post-translational modifications also contribute to regulatory mechanisms, with proteins such as ANGPTL3 and ANGPTL4 inhibiting lipase activities. [18] These interactions represent a form of allosteric or direct protein-protein control, precisely tuning the breakdown of VLDL triglycerides and thus maintaining dynamic regulation of plasma lipid concentrations.
Systemic Lipid Metabolism and Disease Pathogenesis
Section titled “Systemic Lipid Metabolism and Disease Pathogenesis”Lipid metabolic pathways are highly integrated, engaging in extensive crosstalk and network interactions to maintain overall systemic lipid homeostasis. The phospholipid transfer protein (PLTP), for example, mediates the exchange of phospholipids and cholesterol esters among different lipoprotein particles, profoundly influencing the metabolism of both VLDL and high-density lipoprotein (HDL).[23] Research indicates that PLTP overexpression correlates with higher HDL cholesterol and lower triglycerides, underscoring its role in the coordinated remodeling and balancing of circulating lipoproteins. [23]
Dysregulation within these interconnected pathways is a fundamental mechanism underlying various diseases. Genetic polymorphisms linked to altered phospholipid and cholesterol levels have been associated with complex conditions, including type 2 diabetes, bipolar disorder, and rheumatoid arthritis, highlighting how metabolic traits can serve as intermediate phenotypes connecting genetic variance to disease pathology.[17]Specifically, perturbations in VLDL metabolism often manifest as dyslipidemia, particularly hypertriglyceridemia, which is a major risk factor for cardiovascular disease.[22] Mechanisms such as reduced VLDL catabolism due to elevated APOC3 levels or impaired lipase activity from ANGPTL proteins contribute to increased triglycerides. Consequently, genes like HMGCR in cholesterol biosynthesis or LIPC in lipase regulation represent significant therapeutic targets for mitigating lipid disorders and their associated health risks. [19]
Clinical Relevance
Section titled “Clinical Relevance”VLDL Metabolism and Cardiovascular Risk Stratification
Section titled “VLDL Metabolism and Cardiovascular Risk Stratification”The concentrations of very low-density lipoprotein (VLDL) particles and their lipid components, including triglycerides, cholesterol, and phospholipids, are significant indicators for assessing cardiovascular disease (CVD) risk and predicting disease progression. Elevated levels of VLDL-cholesterol and triglycerides are closely associated with an increased risk of atherosclerosis, which is the primary pathology underlying coronary artery disease (CAD) and stroke.[8] Identifying individuals with dysregulated VLDL metabolism allows for early risk stratification, enabling clinicians to implement personalized prevention strategies. For example, specific genetic variants influencing apolipoproteins such as APOC3, a component of VLDL, can impair triglyceride catabolism and hepatic uptake of apoB-containing lipoproteins, leading to higher VLDL levels.[23]Consequently, measuring VLDL-related lipids and identifying such genetic predispositions serves as a prognostic tool to forecast long-term cardiovascular outcomes and guide interventions.
Monitoring changes in VLDL-associated lipids and apolipoproteins provides valuable insights into the effectiveness of lipid-lowering therapies and helps in adjusting treatment regimens. For instance, a null mutation in human APOC3 has been shown to confer a favorable plasma lipid profile characterized by lower triglycerides and VLDL cholesterol, alongside apparent cardioprotection. [20]This evidence highlights the diagnostic utility of assessing VLDL components and related genetic factors in evaluating a patient’s response to treatment or their inherent susceptibility to dyslipidemia. Furthermore, VLDL-cholesterol levels are often considered alongside other lipid parameters, such as LDL cholesterol, HDL cholesterol, and lipoprotein(a) (Lp(a)), to build a comprehensive risk profile, especially given that Lp(a)itself is associated with VLDL-cholesterol levels and carotid artery disease.[24]
Genetic Insights and Therapeutic Strategies for VLDL-Associated Dyslipidemia
Section titled “Genetic Insights and Therapeutic Strategies for VLDL-Associated Dyslipidemia”Genetic studies have unveiled numerous loci that influence VLDL metabolism, providing a foundation for personalized medicine approaches in managing dyslipidemia. Variants in genes like GCKR (specifically the P446L allele) are associated with increased concentrations of APOC3, which in turn inhibits triglyceride catabolism and elevates VLDL levels.[23] Conversely, genetic variants leading to reduced APOC3function are linked to lower VLDL-triglycerides and an apparently protective cardiovascular profile, suggesting that targetingAPOC3 may be a viable therapeutic strategy for hypertriglyceridemia and associated VLDL dysregulation. [20] Other loci near TRIB1, MLXIPL, and ANGPTL3have also been strongly associated with plasma triglyceride concentrations, directly impacting VLDL levels.[5]
Moreover, genes like FADS1-FADS2, which encode desaturases, have demonstrated strong associations with various fatty acids present in serum phospholipids. [3]While phospholipids are integral structural components of VLDL particles, alterations in their fatty acid composition can influence VLDL stability, metabolism, and overall atherogenicity. Understanding these genetic influences can aid in treatment selection by identifying individuals who might benefit from specific dietary modifications or pharmacological agents that modulate fatty acid desaturation or VLDL catabolism. The identification of causal alleles at these loci that influence both lipid levels and cardiovascular disease risk is critical for validating new therapeutic targets and advancing precision medicine for dyslipidemia.[5]
VLDL in Polygenic Dyslipidemia and Comorbid Conditions
Section titled “VLDL in Polygenic Dyslipidemia and Comorbid Conditions”Dysregulation of VLDL metabolism is a central feature of polygenic dyslipidemia, a complex condition where common variants across multiple loci collectively contribute to abnormal lipid profiles. [8] These variations can affect various aspects of VLDL synthesis, secretion, and catabolism. The intricate interplay of these genetic factors with environmental influences can lead to overlapping phenotypes, where high VLDL-cholesterol and triglycerides often coexist with other lipid abnormalities, such as low HDL cholesterol and elevated LDL cholesterol. [5] This broader context is crucial for holistic patient care, as VLDL dysregulation is often interconnected with other metabolic comorbidities.
For instance, individuals with elevated VLDL-cholesterol are frequently observed to have higher rates of type 2 diabetes and hypertension.[24] These conditions further exacerbate dyslipidemia, creating a complex clinical picture that requires integrated management strategies. The identification of genetic variants that affect VLDL levels and are also linked to these comorbidities can improve risk assessment and guide preventive measures. Comprehensive risk assessment must therefore consider the collective impact of genetic predispositions, VLDL-associated lipid levels, and coexisting conditions to develop effective prevention strategies and mitigate the long-term health implications for affected individuals.
References
Section titled “References”[1] Malerba G, et al. “SNPs of the FADS Gene Cluster are Associated with Polyunsaturated Fatty Acids in a Cohort of Patients with Cardiovascular Disease.”Lipids, vol. 43, no. 4, 2008, pp. 289-99.
[2] Schaeffer L, et al. “Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids.” Hum Mol Genet, vol. 15, no. 11, 2006, pp. 1745-56.
[3] Sabatti, C. et al. “Genome-wide association analysis of metabolic traits in a birth cohort from a founder population.”Nat Genet, PMID: 19060910.
[4] Gieger C, et al. “Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum.”PLoS Genet, vol. 4, no. 11, 2008, pp. e1000282.
[5] Kathiresan S, et al. “Common variants at 30 loci contribute to polygenic dyslipidemia.” Nat Genet, vol. 41, no. 1, 2009, pp. 56-65.
[6] Jiang, X. et al. “Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes.”J Clin Invest.
[7] Willer CJ, et al. “Newly identified loci that influence lipid concentrations and risk of coronary artery disease.”Nat Genet, vol. 40, no. 2, 2008, pp. 161-9.
[8] Aulchenko YS, et al. “Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts.”Nat Genet, vol. 40, no. 2, 2008, pp. 181-9.
[9] Burkhardt R, et al. “Common SNPs in HMGCR in Micronesians and Whites Associated With LDL-Cholesterol Levels Affect Alternative Splicing of Exon13.” Arterioscler Thromb Vasc Biol, vol. 28, no. 10, 2008, pp. 1880-6.
[10] Wallace, C. et al. “Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia.”Am J Hum Genet, PMID: 18179892.
[11] Kooner, J. S. et al. “Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides.” Nat Genet, PMID: 18193046.
[12] Bennet, A.M. et al. “Association of apolipoprotein E genotypes with lipid levels and coronary risk.” JAMA, 2007.
[13] Cohen, J et al. “Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.” N Engl J Med, 2006.
[14] Kajinami K, et al. “ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin.”J. Lipid Res., vol. 45, no. 4, 2004, pp. 653-656.
[15] Ek J, et al. “The functional Thr130Ile and Val255Met polymorphisms of the hepatocyte nuclear factor-4alpha (HNF4A): gene associations with type 2 diabetes or altered beta-cell function among Danes.” J. Clin. Endocrinol. Metab., vol. 90, no. 5, 2005, pp. 3054-3059.
[16] Romeo S, et al. “Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL.” Nat. Genet., vol. 39, no. 4, 2007, pp. 513-516.
[17] Gieger, C. et al. “Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum.”PLoS Genet, PMID: 19043545.
[18] Willer, C. J. et al. “Newly identified loci that influence lipid concentrations and risk of coronary artery disease.”Nat Genet, PMID: 18193043.
[19] Burkhardt, R. et al. “Common SNPs in HMGCR in Micronesians and Caucasians associated with LDL-cholesterol levels affect alternative splicing.” Arterioscler Thromb Vasc Biol, PMID: 18802019.
[20] Pollin TI, et al. “A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.” Science, vol. 322, no. 5908, 2008, pp. 1702-5.
[21] Aalto-Setala K, et al. “Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.”J Clin Invest, vol. 90, no. 5, 1992, pp. 1889-900.
[22] Aulchenko, Y. S. et al. “Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts.”Nat Genet, PMID: 19060911.
[23] Kathiresan, S. et al. “Common variants at 30 loci contribute to polygenic dyslipidemia.” Nat Genet, PMID: 19060906.
[24] Ober, C., et al. “Genome-wide association study of plasma lipoprotein(a) levels identifies multiple genes on chromosome 6q.”J Lipid Res, vol. 50, no. 7, 2009, pp. 1324-33.